Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IGMS
IGMS logo

IGMS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
390.15M
Low
--
Amount
--
EV/EBITDA(TTM)
-1.59
Total Shares
--
EV
-27.73M
EV/OCF(TTM)
--
P/S(TTM)
0.54
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Show More

Events Timeline

(ET)
2025-07-01
09:04:30
IGM Biosciences be acquired by Concentra for $1.247 in cash per share
select

News

Businesswire
3.5
2025-12-17Businesswire
iGMS Launches AI Features Reducing Guest Communication Time to 1.5 Hours
  • AI Feature Upgrade: iGMS's Pro+ plan introduces AI tools that reduce guest communication time for short-term rental hosts from 12 hours per week to just 1.5 hours, enabling hosts to focus more on improving their business, thereby enhancing operational efficiency and profitability.
  • User Testing Feedback: The new features demonstrated significant time-saving results in tests with nearly 8,000 Airbnb hosts worldwide, indicating a major leap in intelligent hosting and further solidifying iGMS's position as an industry leader.
  • Pricing Strategy: The Pro+ plan is now available to new and existing customers at a price of $16 per property per month with no booking fees, and a 14-day free trial is offered to attract more hosts to utilize its advanced AI tools, aiming to increase market share.
  • Market Positioning: By redesigning its platform around AI, iGMS aims to provide efficient and intelligent operational solutions for professional hosts and property managers, thereby gaining a strategic advantage in the highly competitive short-term rental market.
NASDAQ.COM
9.5
2025-08-01NASDAQ.COM
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
  • Earnings Performance: IGM Biosciences, Inc. reported quarterly earnings of $1.58 per share, significantly exceeding expectations and showing a substantial improvement from a loss of $0.79 per share a year ago, while revenues reached $143.62 million, far surpassing estimates.

  • Market Outlook: Despite the positive earnings report, IGM's stock has underperformed this year, with a Zacks Rank of #5 (Strong Sell), indicating expected continued underperformance in the near future, influenced by unfavorable estimate revisions and industry trends.

Globenewswire
7.0
2025-07-05Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, SPTN, IGMS on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating Olo Inc., SpartanNash Company, and IGM Biosciences, Inc. for potential violations of federal securities laws related to their recent sales and transactions.

  • Legal Support for Shareholders: The law firm offers free consultations to shareholders regarding their legal rights and options, aiming to seek increased compensation or additional disclosures from the companies involved.

Globenewswire
8.5
2025-07-02Globenewswire
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of IGM Biosciences, Inc. (NASDAQ: IGMS)
  • Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

  • Investigation of IGM Biosciences: The firm is currently investigating the merger of IGM Biosciences, Inc. with Concentra Biosciences, LLC, which involves a cash offer and contingent value rights for shareholders.

PRnewswire
7.0
2025-07-01PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, IGMS, SPTN, DNOW on Behalf of Shareholders
  • Investor Rights Investigation: Halper Sadeh LLC is investigating several companies, including Guaranty Bancshares, IGM Biosciences, SpartanNash Company, and DNOW Inc., for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed sales and mergers.

  • Legal Support for Shareholders: The law firm offers free consultations to shareholders affected by these transactions, aiming to seek increased consideration or additional disclosures on behalf of investors.

Yahoo Finance
4.0
2025-06-12Yahoo Finance
IGM Biosciences price target lowered to $1 from $2 at Truist
  • Truist's Price Target Adjustment: Truist has lowered the price target for IGM Biosciences (IGMS) from $2 to $1 while maintaining a Hold rating, reflecting updates based on Q1 financial results and future outlook.

  • Company Developments: The firm is awaiting any announcements regarding a strategic pivot from IGM Biosciences, amidst reports of increased net loss, termination of a lease agreement, and workforce cuts.

Wall Street analysts forecast IGMS stock price to rise
2 Analyst Rating
Wall Street analysts forecast IGMS stock price to rise
0 Buy
2 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
1.00
Averages
1.00
High
1.00
Current: 0.000
sliders
Low
1.00
Averages
1.00
High
1.00
BofA
Underperform -> No Rating
downgrade
$1.247
AI Analysis
2025-07-01
Reason
BofA
Price Target
$1.247
AI Analysis
2025-07-01
downgrade
Underperform -> No Rating
Reason
BofA moves to No Rating from Underperform on IGM Biosciences after the company announced an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash and a variable non-tradable contingent value right. IGM shares are no longer trading on fundamentals following the deal announcement, the analyst says.
Truist
Hold
downgrade
$2 -> $1
2025-06-11
Reason
Truist
Price Target
$2 -> $1
2025-06-11
downgrade
Hold
Reason
Truist lowered the firm's price target on IGM Biosciences to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the company's forward outlook, adding that it is waiting for any potential announcement regarding a strategic pivot from the company, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IGMS
Unlock Now

Valuation Metrics

The current forward P/E ratio for IGM Biosciences Inc (IGMS.O) is -1.45, compared to its 5-year average forward P/E of -4.42. For a more detailed relative valuation and DCF analysis to assess IGM Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.42
Current PE
-1.45
Overvalued PE
-0.72
Undervalued PE
-8.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.04
Current EV/EBITDA
2.09
Overvalued EV/EBITDA
1.01
Undervalued EV/EBITDA
-5.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
82.04
Current PS
11.79
Overvalued PS
200.84
Undervalued PS
-36.75

Financials

AI Analysis
Annual
Quarterly

Whales Holding IGMS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IGM Biosciences Inc (IGMS) stock price today?

The current price of IGMS is 0 USD — it has increased 0

What is IGM Biosciences Inc (IGMS)'s business?

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

What is the price predicton of IGMS Stock?

Wall Street analysts forecast IGMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGMS is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IGM Biosciences Inc (IGMS)'s revenue for the last quarter?

IGM Biosciences Inc revenue for the last quarter amounts to 143.62M USD, increased 11353.19

What is IGM Biosciences Inc (IGMS)'s earnings per share (EPS) for the last quarter?

IGM Biosciences Inc. EPS for the last quarter amounts to 1.58 USD, decreased -300.00

How many employees does IGM Biosciences Inc (IGMS). have?

IGM Biosciences Inc (IGMS) has 149 emplpoyees as of March 19 2026.

What is IGM Biosciences Inc (IGMS) market cap?

Today IGMS has the market capitalization of 390.15M USD.